The role of bortezomib in the treatment of acute lymphoblastic leukemia

被引：8
作者：
Zahid, Mohammad Faizan [1 ]
机构：
[1] Aga Khan Univ, Karachi, Pakistan
来源：
FUTURE ONCOLOGY | 2016年 / 12卷 / 16期
关键词：
acute lymphoblastic leukemia; acute lymphocytic leukemia; bortezomib; proteasome inhibitors; treatment; PROTEASOME INHIBITOR BORTEZOMIB; PHASE-I; KAPPA-B; THERAPEUTIC ADVANCES; CHILDHOOD LEUKEMIA; CHEMOTHERAPY; ACTIVATION; TACL;
D O I：
10.2217/fon-2016-0126
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1861 / 1864
页数：4
相关论文
共 27 条
  • [1] Novel agents for the treatment of childhood acute leukemia
    Annesley, Colleen E.
    Brown, Patrick
    [J]. THERAPEUTIC ADVANCES IN HEMATOLOGY, 2015, 6 (02) : 61 - 79
  • [2] Synergistic Activity of Bortezomib and HDACi in Preclinical Models of B-cell Precursor Acute Lymphoblastic Leukemia via Modulation of p53, PI3K/AKT, and NF-κB
    Bastian, Lorenz
    Hof, Jana
    Pfau, Madlen
    Fichtner, Iduna
    Eckert, Cornelia
    Henze, Guenter
    Prada, Javier
    von Stackelberg, Arend
    Seeger, Karl
    Shalapour, Shabnam
    [J]. CLINICAL CANCER RESEARCH, 2013, 19 (06) : 1445 - 1457
  • [3] Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
    Boccadoro, Mario
    Morgan, Gareth
    Cavenagh, Jamie
    [J]. CANCER CELL INTERNATIONAL, 2005, 5 (1)
  • [4] Brown RE, 2004, ANN CLIN LAB SCI, V34, P203
  • [5] Phase I study of bortezomib in refractory or relapsed acute leukemias
    Cortes, J
    Thomas, D
    Koller, C
    Giles, F
    Estey, E
    Faderl, S
    Garcia-Manero, G
    McConkey, D
    Patel, G
    Guerciolini, R
    Wright, J
    Kantarjian, H
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (10) : 3371 - 3376
  • [6] Emerging Treatments in Acute Lymphoblastic Leukemia
    Crazzolara, R.
    Bendall, L.
    [J]. CURRENT CANCER DRUG TARGETS, 2009, 9 (01) : 19 - 31
  • [7] Recent Advancements of Bortezomib in Acute Lymphocytic Leukemia Treatment
    Du, Xiao-Li
    Chen, Qi
    [J]. ACTA HAEMATOLOGICA, 2013, 129 (04) : 207 - 214
  • [8] Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study
    Fielding, Adele K.
    Richards, Susan M.
    Chopra, Rajesh
    Lazarus, Hillard M.
    Litzow, Mark R.
    Buck, Georgina
    Durrant, I. Jill
    Luger, Selina M.
    Marks, David I.
    Franklin, Ian M.
    McMillan, Andrew K.
    Tallman, Martin S.
    Rowe, Jacob M.
    Goldstone, Anthony H.
    [J]. BLOOD, 2007, 109 (03) : 944 - 950
  • [9] A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: A Children's Oncology Group study
    Horton, Terzah M.
    Pati, Debananda
    Plon, Sharon E.
    Thompson, Patrick A.
    Bomgaars, Lisa R.
    Adamson, Peter C.
    Ingle, Ashish M.
    Wright, John
    Brockman, Adam H.
    Paton, Martin
    Blaney, Susan M.
    [J]. CLINICAL CANCER RESEARCH, 2007, 13 (05) : 1516 - 1522
  • [10] Bortezomib interactions with chemotherapy agents in acute leukemia in vitro
    Horton, TM
    Gannavarapu, A
    Blaney, SM
    D'Argenio, DZ
    Plon, SE
    Berg, SL
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (01) : 13 - 23
123